An experimental form of immunotherapy that uses an individual’s own tumour-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health.

Many people with metastatic breast cancer can mount an immune reaction against their tumours, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumour-infiltrating lymphocytes (TILs).

In a clinical trial of 42 women with metastatic breast cancer, 28 (or 67%) generated an immune reaction against their cancer. The approach was used to treat six women, half of whom experienced measurable tumour shrinkage. Results from the trial appeared in the Journal of Clinical Oncology.

“It’s popular dogma that hormone receptor-positive breast cancers are not capable of provoking an immune response and are not susceptible to immunotherapy,” said study leader Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch in NCI’s Center for Cancer Research.

“The findings suggest that this form of immunotherapy can be used to treat some people with metastatic breast cancer who have exhausted all other treatment options.”

Immunotherapy is a treatment that helps a person’s own immune system fight cancer. However, most available immunotherapies, such as immune checkpoint inhibitors, have shown limited effectiveness against hormone receptor–positive breast cancers, which are the majority of breast cancers.

The immunotherapy approach used in the trial was pioneered in the late 1980s by Dr. Rosenberg and his colleagues at NCI. It relies on TILs, T cells that are found in and around the tumour.

TILs can target tumour cells that have specific proteins on their surface, called neoantigens, that the immune cells recognize. Neoantigens are produced when mutations occur in tumour DNA.

Other forms of immunotherapy have been found to be effective in treating cancers, such as melanoma, that have many mutations, and therefore many neoantigens. Its effectiveness in cancers that have fewer neoantigens, such as breast cancer, however, has been less clear. 

The results of the new study come from an ongoing phase 2 clinical trial being carried out by Dr Rosenberg and his colleagues. This trial was designed to see if the immunotherapy approach could lead to tumour regressions in people with metastatic epithelial cancers, including breast cancer.

In 2018, the researchers showed that one woman with metastatic breast cancer who was treated in this trial had complete tumour shrinkage, known as a complete response.

In the trial, the researchers used whole-genome sequencing to identify mutations in tumour samples from 42 women with metastatic breast cancer whose cancers had progressed despite all other treatments.

The researchers then isolated TILs from the tumour samples and, in lab tests, tested their reactivity against neoantigens produced by the different mutations in the tumour.

Twenty-eight women had TILs that recognised at least one neoantigen. Nearly all the neoantigens identified were unique to each patient.

“It’s fascinating that the Achilles’ heel of these cancers can potentially be the very gene mutations that caused cancer,” said Dr. Rosenberg. “Since that 2018 study, we now have information on 42 patients, showing that the majority give rise to immune reactions.”

For the six women treated, the researchers took the reactive TILs and grew them to large numbers in the lab.

They then returned the immune cells to each patient via intravenous infusion. All the patients were also given four doses of the immune checkpoint inhibitor pembrolizumab (Keytruda) before the infusion to prevent the newly introduced T cells from becoming inactivated.

After the treatment, tumours shrank in three of the six women. One is the original woman reported in the 2018 study, who remains cancer-free to this day.

The other two women had tumour shrinkage of 52% and 69% after six months and 10 months, respectively. However, some disease returned and was surgically removed.

Those women now have no evidence of cancer approximately five years and 3.5 years, respectively, after their TIL treatment.

The researchers acknowledged that the use of pembrolizumab, which has been approved for some early-stage breast cancers, may raise uncertainties about its influence on the outcome of TIL therapy.

However, they said, treatment with such checkpoint inhibitors alone has not led to sustained tumour shrinkage in people with hormone receptor-positive metastatic breast cancer.

Dr. Rosenberg said that with the anticipated opening early this year of NCI’s new building devoted to cell-based therapies, he and his colleagues can begin treating more individuals with metastatic breast cancer as part of the ongoing clinical trial. He noted that this new immunotherapy approach could potentially be used for people with other types of cancer as well.

“We’re using a patient’s own lymphocytes as a drug to treat the cancer by targeting the unique mutations in that cancer,” he said. “This is a highly personalised treatment.”

Source: National Institutes of Health (NIH)